C CAR 031
Alternative Names: Anti-GPC3 CAR-T cell therapy - Astrazeneca; AZD-7003; C-CAR031Latest Information Update: 10 Jun 2024
At a glance
- Originator AstraZeneca
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Liver cancer
Most Recent Events
- 04 Jun 2024 Updated efficacy and adverse events data from a phase I trial in Liver cancer released by AbelZeta Pharma
- 31 May 2024 Updated efficacy, adverse events and pharmacokinetics data from a phase I trial in Liver cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 07 Dec 2023 AbelZeta Pharma and AstraZeneca enter into an agreement to co-develop C CAR 031 .